ArticleImmunotherapy advances2022

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.

Stephanie Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.